Application of TLR8 activator in preparing tuberculosis vaccine adjuvant and tuberculosis vaccine prepared from TLR8 activator

Abstract

The invention belongs to the field of biological medicine and specifically relates to application of a TLR8 activator in preparing a tuberculosis vaccine adjuvant and a tuberculosis vaccine prepared from the TLR8 activator. The TLR8 activator has the following structural formula: FORMULA shown in the description. Research finds that the TLR8 activator TL8-506 provides a protection effect when theimmunized mouse is attacked by mycobacterium tuberculosis, and thus can be adopted as an adjuvant of the tuberculosis vaccine; according to further research, the TLR8 activator TL8-506 combined with aluminum hydroxide gel provides a stronger protection effect than aluminum hydroxide gel when the immunized mouse is attacked by mycobacterium tuberculosis.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the use of a TLR8 activator in preparing a tuberculosis vaccine adjuvant and the prepared tuberculosis vaccine. Background technique [0002] Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (M.tuberculosis, MTB), which seriously endangers human health. Tuberculosis is the biggest killer worldwide after AIDS caused by a single infectious agent. Currently, 1 / 3 of the world's population has been infected with MTB. According to WHO statistics, in recent years, there are about 9 million new tuberculosis cases and 1.5 million deaths in the world every year. my country is one of the 22 countries with a high burden of tuberculosis in the world, and the number of cases is second only to India, ranking second in the world. Bacillus Calmette Guérin (BCG) is currently the only tuberculosis vaccine approved for use in humans. Although it has a certain ...

AI Technical Summary

Problems solved by technology

[0004] However, there have been no relevant reports on the use of TLR8 receptor agonists in the preparation of tuberculosis vaccine adjuvants, which may be due to the following reasons: First, TLR7 and TLR8 are involved in intracellular localization, ligand types (ssRNA, etc.), downstream pathways, etc. Very similarly, less specific activators such as R848 can activate TLR7 and TLR8 at the same time, and induce the immune response caused by the simultaneous activation of both, but the differences between TLR7 and TLR8, as well as the interaction between the two, make Individually studying the in vivo effects of specifically activating TLR8 becomes an open question

Secondly, as the most widely used experimental animal, the function of TLR8 in mice is significantly different from that of human TLR8, so it cannot be directly used as an in vivo model for the study of TLR8 function

Images